Andrabi Syed Waseem, Makker Giresh Chandra, Makker Renu, Mishra Geetanjali, Singh Rajender
Department of Zoology, University of Lucknow, Lucknow, India.
Makker IVF Centre, Lucknow, India.
Clin Exp Reprod Med. 2022 Mar;49(1):57-61. doi: 10.5653/cerm.2021.04742. Epub 2022 Feb 28.
This study aimed to evaluate whether human chorionic gonadotropin (hCG) therapy is beneficial for improving semen parameters and clinical hypogonadism symptoms in hypogonadic oligozoospermic or severe oligozoospermic men with low or borderline testosterone levels.
A weekly dose of 250 μg (equivalent to approximately 6,500 IU) of hCG was administered subcutaneously for 3-6 months to 56 hypogonadic oligozoospermic or severe oligozoospermic men. Semen, biochemical, and genetic analyses were performed before the start of treatment followed by analyzing semen parameters every 3 months after the start of therapy. We grouped participants into responders and non-responders depending on positive changes in semen parameters.
Out of 56 men, 47 (83.93%) responded, while 9 (16.07%) did not. Upon statistical analysis, it was found that age did not affect the overall outcomes (p=0.292); however, men with higher body mass index (BMI; 28.09±3.48 kg/m2 ) showed better outcomes than those with low BMI (25.33±3.06 kg/m2 ) (p=0.042). The duration of therapy (in months) was higher in non-responders than in responders (p=0.020). We found significant improvements in sperm concentration (p=0.006) and count (p=0.005) after 3 months of therapy. Sperm motility and progressive motility were also found to be higher in responders, but did not show statistically significant changes.
We conclude that hCG therapy can be beneficial in men with hypogonadic oligozoospermia or severe oligozoospermia.
本研究旨在评估人绒毛膜促性腺激素（hCG）疗法是否有助于改善性腺功能减退性少精子症或严重少精子症且睾酮水平低或临界的男性的精液参数和临床性腺功能减退症状。
对56例性腺功能减退性少精子症或严重少精子症男性皮下注射每周剂量250μg（约相当于6500IU）的hCG，持续3 - 6个月。在治疗开始前进行精液、生化和基因分析，治疗开始后每3个月分析精液参数。根据精液参数的阳性变化将参与者分为反应者和无反应者。
56名男性中，47名（83.93%）有反应，而9名（16.07%）无反应。经统计分析发现，年龄不影响总体结果（p = 0.292）；然而，体重指数（BMI）较高（28.09±3.48kg/m²）的男性比BMI较低（25.33±3.06kg/m²）的男性效果更好（p = 0.042）。无反应者的治疗持续时间（月）高于反应者（p = 0.020）。治疗3个月后，精子浓度（p = 0.006）和计数（p = 0.005）有显著改善。反应者的精子活力和前向运动能力也较高，但未显示出统计学上的显著变化。
我们得出结论，hCG疗法对性腺功能减退性少精子症或严重少精子症男性可能有益。
